JP2024516795A5 - - Google Patents
Info
- Publication number
- JP2024516795A5 JP2024516795A5 JP2023562510A JP2023562510A JP2024516795A5 JP 2024516795 A5 JP2024516795 A5 JP 2024516795A5 JP 2023562510 A JP2023562510 A JP 2023562510A JP 2023562510 A JP2023562510 A JP 2023562510A JP 2024516795 A5 JP2024516795 A5 JP 2024516795A5
- Authority
- JP
- Japan
- Prior art keywords
- cancer
- pharmaceutically acceptable
- everolimus
- amsenestrant
- pharmaceutical composition
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP21315063.4 | 2021-04-12 | ||
| EP21315063 | 2021-04-12 | ||
| PCT/EP2022/059704 WO2022218958A1 (en) | 2021-04-12 | 2022-04-12 | Combination comprising everolimus and amcenestrant |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2024516795A JP2024516795A (ja) | 2024-04-17 |
| JP2024516795A5 true JP2024516795A5 (https=) | 2025-04-16 |
Family
ID=75825773
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023562510A Pending JP2024516795A (ja) | 2021-04-12 | 2022-04-12 | エベロリムスおよびアムセネストラントを含む組合せ物 |
Country Status (8)
| Country | Link |
|---|---|
| US (1) | US20240197692A1 (https=) |
| EP (1) | EP4322942B1 (https=) |
| JP (1) | JP2024516795A (https=) |
| CN (1) | CN117177743A (https=) |
| AR (1) | AR125330A1 (https=) |
| ES (1) | ES3036485T3 (https=) |
| TW (1) | TW202304424A (https=) |
| WO (1) | WO2022218958A1 (https=) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| BR112021003440A2 (pt) | 2018-09-07 | 2021-05-18 | Sanofi | sais de 6-(2,4-diclorofenil)-5-[4-[(3s)-1-(3-fluoropropil) pirrolidin-3-il]oxifenil]-8,9-di-hidro-7h-benzo[7]anuleno-2-carboxilato de metila e seu processo de preparação |
| EP4037768B1 (en) | 2019-10-01 | 2023-10-11 | Sanofi | Novel substituted 6,7-dihydro-5h-benzo[7]annulene compounds, processes for their preparation and therapeutic uses thereof |
| AU2020399168A1 (en) | 2019-12-09 | 2022-07-28 | Sanofi | Crystalline form of a 7H-benzo[7]annulene-2-carboxylic acid derivative |
| TW202146007A (zh) | 2020-02-27 | 2021-12-16 | 法商賽諾菲公司 | 包含阿培利司（ａｌｐｅｌｉｓｉｂ）與６－（２，４－二氯苯基）－５－［４－［（３ｓ）－１－（３－氟丙基）吡咯啶－３－基］氧苯基］－８，９－二氫－７ｈ－苯并［７］輪烯－２－羧酸之組合 |
| TW202233572A (zh) | 2020-10-19 | 2022-09-01 | 法商賽諾菲公司 | 新穎之經取代的6,7-二氫-5h-苯並[7]輪烯衍生物，其製備方法及其治療用途 |
| WO2022084280A1 (en) | 2020-10-19 | 2022-04-28 | Sanofi | Substituted 6,7-dihydro-5h-benzo[7]annulene compounds and their derivatives, processes for their preparation and therapeutic uses thereof |
| TW202543650A (zh) | 2024-03-08 | 2025-11-16 | 美商海爾達醫療運營公司 | 異雙官能化合物及其在治療疾病中之用途 |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN105828822B (zh) * | 2013-08-14 | 2019-10-18 | 诺华股份有限公司 | 用于治疗癌症的组合疗法 |
| EA034994B1 (ru) | 2016-02-15 | 2020-04-15 | Санофи | 6,7-дигидро-5h-бензо[7]аннуленовые производные в качестве модуляторов эстрогеновых рецепторов |
| CA3169679A1 (en) * | 2020-03-06 | 2021-09-10 | Olema Pharmaceuticals, Inc. | Methods of treating estrogen receptor-associated diseases |
-
2022
- 2022-04-08 TW TW111113410A patent/TW202304424A/zh unknown
- 2022-04-11 AR ARP220100914A patent/AR125330A1/es not_active Application Discontinuation
- 2022-04-12 WO PCT/EP2022/059704 patent/WO2022218958A1/en not_active Ceased
- 2022-04-12 ES ES22722256T patent/ES3036485T3/es active Active
- 2022-04-12 EP EP22722256.9A patent/EP4322942B1/en active Active
- 2022-04-12 CN CN202280027705.5A patent/CN117177743A/zh active Pending
- 2022-04-12 US US18/286,496 patent/US20240197692A1/en active Pending
- 2022-04-12 JP JP2023562510A patent/JP2024516795A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2024516795A5 (https=) | ||
| JP2024516363A5 (https=) | ||
| JP2023550149A5 (https=) | ||
| JP2023516951A5 (https=) | ||
| JP2023503309A5 (https=) | ||
| RU2020107416A (ru) | Комбинация, содержащая палбоциклиб и 6-(2,4-дихлорфенил)-5-[4-[(3s)-1-(3-фторпропил)пиррролидин-3-ил]-8,9-дигидро-7h-бензо[7]аннулен-2-карбоновую кислоту, и ее применение для лечения рака | |
| RU2010140682A (ru) | Способ лечения пациента от инфекции, фармацевтическая композиция (варианты) и лекарственное средство | |
| JP2023541432A5 (https=) | ||
| RU2012106620A (ru) | Комбинации и способы введения терапевтических средств и комбинированной терапии | |
| RU2008138560A (ru) | Улучшенные способы лечения опухолей | |
| JP2023541430A5 (https=) | ||
| CN102065865B (zh) | 多发性骨髓瘤治疗 | |
| JP2012515184A (ja) | 大腸がんの治療方法 | |
| JP2020521797A5 (https=) | ||
| AR125330A1 (es) | Combinación que comprende everolimus y amcenestrant | |
| JP6063550B2 (ja) | 薬物誘発性手足症候群を治療するための組成物および方法 | |
| JP2013518124A5 (https=) | ||
| JP2016502981A5 (https=) | ||
| JP2008514577A5 (https=) | ||
| RU2019130325A (ru) | ДОЗА И СХЕМА ВВЕДЕНИЯ ИНГИБИТОРА ВЗАИМОДЕЙСТВИЯ HDM2 С p53 ПРИ ГЕМАТОЛОГИЧЕСКИХ ОПУХОЛЯХ | |
| MX2014002663A (es) | Nuevo esquema de administracion de la n-hidroxi-4-{2-[3-(n,n-dimet ilaminometil)benzofuran-2-ilcarbonilamino]etoxi}benzamida. | |
| JP2021522246A5 (https=) | ||
| JP2008517991A5 (https=) | ||
| JP2024540439A5 (https=) | ||
| JPWO2021206167A5 (https=) |